Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

St. Jude Eyes Possible Acquisition Of Heart Failure Monitor Firm CardioMEMS

This article was originally published in The Gray Sheet

Executive Summary

St. Jude Medical is placing a $60 million bet on wireless implantable heart failure monitor developer CardioMEMS and has acquired an exclusive option to own the entire company via a Sept. 7 agreement

You may also be interested in...



St. Jude: CardioMEMS’ Heart Failure Data Reflects Major Opportunity

With the publication of the CHAMPION clinical trial results, CardioMEMS and its suitor St. Jude Medical took another step toward leading the pack in what they say is a multi-billion dollar market opportunity in hemodynamic heart failure monitoring.

St. Jude: CardioMEMS’ Heart Failure Data Reflects Major Opportunity

With the publication of the CHAMPION clinical trial results, CardioMEMS and its suitor St. Jude Medical took another step toward leading the pack in what they say is a multi-billion dollar market opportunity in hemodynamic heart failure monitoring.

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2010

Medical device financings during the third quarter of 2010 brought in $997 million, an increase of 82% from the second quarter's $548 million. While Q3 M&A activity was down slightly from last quarter - only 15 mergers were completed, compared with 18 in Q2 - more money was involved: an impressive $6.7 billion. The venture rounds for PacBio and Complete Genomics boosted late-stage VC money to $171 million in the third quarter, two-thirds of the entire amount for the in vitro diagnostics/research industry. Despite only five acquisitions closing during the third quarter, the M&A dollar volume for the IVD/research industry was just north of $2 billion.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel